Log in
OTCMKTS:OSIR

Osiris Therapeutics Stock Forecast, Price & News

$18.99
0.00 (0.00 %)
(As of 04/17/2019)
Add
Compare
Today's Range
$18.99
Now: $18.99
$18.99
50-Day Range
$18.99
MA: $18.99
$18.99
52-Week Range
$7.01
Now: $18.99
$19.30
VolumeN/A
Average Volume205,753 shs
Market Capitalization$655.69 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
Read More
Osiris Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolOTCMKTS:OSIR
Previous SymbolNASDAQ:OSIR
CUSIP68827R10
Phone443-545-1800
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$655.69 million
Next Earnings DateN/A
OptionableOptionable
$18.99
0.00 (0.00 %)
(As of 04/17/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive OSIR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSIR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Osiris Therapeutics (OTCMKTS:OSIR) Frequently Asked Questions

How has Osiris Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Osiris Therapeutics' stock was trading at $18.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OSIR shares have increased by 0.0% and is now trading at $18.99.
View which stocks have been most impacted by COVID-19
.

Who are some of Osiris Therapeutics' key competitors?

What other stocks do shareholders of Osiris Therapeutics own?

Who are Osiris Therapeutics' key executives?

Osiris Therapeutics' management team includes the following people:
  • Mr. Jason Keefer, Interim Pres & CEO (Age 46)
  • Dr. Alla N. Danilkovitch, Chief Scientific Officer (Age 54)
  • Mr. Joel David Rogers, Interim Chief Financial Officer (Age 56)
  • Mr. Edward Yip, Chief Legal Officer & Corp. Sec.
  • Mr. Laine Dyess, VP of Sales

What is Osiris Therapeutics' stock symbol?

Osiris Therapeutics trades on the OTCMKTS under the ticker symbol "OSIR."

How do I buy shares of Osiris Therapeutics?

Shares of OSIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Osiris Therapeutics' stock price today?

One share of OSIR stock can currently be purchased for approximately $18.99.

How big of a company is Osiris Therapeutics?

Osiris Therapeutics has a market capitalization of $655.69 million.

What is Osiris Therapeutics' official website?

The official website for Osiris Therapeutics is www.osiristx.com.

How can I contact Osiris Therapeutics?

Osiris Therapeutics' mailing address is 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD, 21046. The biotechnology company can be reached via phone at 443-545-1800 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.